Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Simcere Pharmaceutical Group - Home
Simcere Zaiming will Present 8 Research Abstracts at the 2023 AACR ...
Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors ...
Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group | Administration and support services ...
Simcere gets China okay for G1's bone marrow protector Cosela ...
Simcere Pharmaceutical's SIM0508 Reaches First Patient Dosing in Global ...
[PPT] - Simcere Pharmaceutical Group Simcere Pharmaceutical Group CIBC ...
Simcere
Simcere Pharmaceutical's Edaravone and Borneol Sublingual Tablets ...
Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC ...
| Simcere Pharmaceutical: A leading innovator from China that Links to ...
Simcere Pharmaceuticals - Cell and Gene Therapy Innovation Center - HGA
Simcere Pharmaceutical Group | LinkedIn
Boehringer Ingelheim and Simcere Pharmaceutical ~$1.26B Deal to Develop ...
Simcere Pharma Opens Innovation Center in Hong Kong to Accelerate R&D ...
Simcere Pharmaceutical Group Licenses First In Class TL1A IL23p19 ...
Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment ...
Simcere Pharmaceutical Group(SCR.NYSE) - ResearchInChina
Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC ...
Simcere Pops After Chinese Regulator Says Firm’s Oral Covid-19 Drug May ...
PPT - Pipeline Review on Simcere Pharmaceutical Group - Product In ...
Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal ...
Collaborations | G1 Therapeutics, Inc.
Simcere’s Covid-19 Pill Goes on Sale in China at Less Than Half the ...
Simcere’s Covid-19 Prevention Pill Is First in China to Get Green Light ...
